Cryoablation Plus Immune Checkpoint Inhibitors Enhanced Dendritic Cell and T Cell Activation in TNBC Murine Model.

Area of Science:

• Immunology
• Oncology
• Cancer Research

Background:

• Cryoablation utilizes freeze-thaw cycles to destroy tumors and preserve antigens, potentially stimulating anti-tumor immunity.
• Triple-negative breast cancer (TNBC) has limited treatment options, and immune checkpoint inhibitors (ICIs) show benefit but cause toxicities.
• Combining cryoablation with ICIs may enhance efficacy and reduce ICI dosage in TNBC.

Purpose of the Study:

• To investigate the therapeutic impact of combining cryoablation with ICIs in a murine TNBC model.
• To evaluate the potential of this combination to enhance anti-tumor immunity and minimize treatment toxicity.

Main Methods:

• An orthotopic bilateral murine TNBC model was used.
• Primary tumors underwent cryoablation, while abscopal tumors were untreated.
• Mice received intra-peritoneal injections of PBS or ICIs (anti-CTLA-4, PD-1, PD-L1) pre- and post-cryoablation.
• Immune profiling of tumors, lymph nodes, spleen, and blood was performed.

Main Results:

• Combination of cryoablation with anti-CTLA-4 significantly enhanced systemic T cell activation compared to cryoablation alone or with PD-1/PD-L1 blockade.
• Anti-CTLA-4 combination increased activated CD4+ and CD8+ T cells in abscopal tumors.
• This combination also increased the frequency and activation of conventional dendritic cells in tumor-draining lymph nodes.

Conclusions:

• Combination therapy of cryoablation and anti-CTLA-4 enhances systemic anti-tumor immunity by improving antigen presentation.
• This strategy shows potential for preventing tumor recurrence and metastasis while reducing treatment toxicity.
• Further investigation is warranted for this combination therapy in TNBC treatment.